Dabomb Protein BiotechROCO:6578 +0.30%59 Current Ratio is 2.67 as of Dec. 2025, which is 15% above its 10-year median of 2.32. GuruFocus rates ROCO:6578 with a GF Score™ of 59/100 and a GF Value™ of NT$14.55 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 1,986 Consumer Packaged Goods companies, Dabomb Protein Biotech ranks better than 70.24% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Dabomb Protein Biotech's current ratio for the quarter that ended in Dec. 2025 was 2.67.
Dabomb Protein Biotech has a current ratio of 2.67. It generally indicates good short-term financial strength.
The historical rank and industry rank for Dabomb Protein Biotech's Current Ratio or its related term are showing as below:
ROCO:6578'
s Current Ratio Range Over the Past 10 Years
Min: 1.57 Med: 2.32 Max: 3.81
Current: 2.67
During the past 13 years, Dabomb Protein Biotech's highest Current Ratio was 3.81. The lowest was 1.57. And the median was 2.32.
ROCO:6578's Current Ratio is ranked better than 70.24% of 1986
companies
in the Consumer Packaged Goods industry
Industry Median: 1.73
vs ROCO:6578: 2.67
Dabomb Protein Biotech (ROCO:6578) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Dabomb Protein Biotech Current Ratio Related Terms
Dabomb Protein Biotech Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Dabomb Protein Biotech's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dabomb Protein Biotech Current Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Dabomb Protein Biotech's Current Ratio distribution charts can be found below:
* The bar in red indicates where Dabomb Protein Biotech's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dabomb Protein Biotech (ROCO:6578) has a Current Ratio of 2.67 as of Dec. 2025. This is 15% above median its historical median of 2.32. Over the past decade, Dabomb Protein Biotech's Current Ratio has ranged from 1.57 to 3.81. According to the industry distribution chart, Dabomb Protein Biotech ranks #591 out of 1986 companies in the Consumer Packaged Goods industry, placing it in the top 29.8%.
Is Dabomb Protein Biotech's Current Ratio too high?
Dabomb Protein Biotech's current Current Ratio of 2.67 is 15% above median its 10-year median of 2.32. Over the past 10 years, this metric has ranged from a low of 1.57 to a high of 3.81. The Consumer Packaged Goods industry median Current Ratio is 1.73. Dabomb Protein Biotech's value of 2.67 is 54.3% above this industry median. Based on the distribution chart, Dabomb Protein Biotech ranks #591 out of 1986 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Dabomb Protein Biotech has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dabomb Protein Biotech's Current Ratio compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Dabomb Protein Biotech ranks #591 out of 1986 companies for Current Ratio. This puts Dabomb Protein Biotech in the upper half of its industry. The industry median Current Ratio is 1.73. Dabomb Protein Biotech's value of 2.67 is 54.3% above this benchmark. Historically, Dabomb Protein Biotech's own Current Ratio has ranged from 1.57 to 3.81 over the past decade. While the company's 10-year median is 2.32 vs. the industry median of 1.73, Dabomb Protein Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Consumer Packaged Goods company?
The median Current Ratio among Consumer Packaged Goods companies is 1.73, based on 1,986 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dabomb Protein Biotech's current Current Ratio of 2.67 is 54.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Consumer Packaged Goods industry, the median Current Ratio is 1.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dabomb Protein Biotech's current Current Ratio is 2.67, which is 15% above median its own 10-year median of 2.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dabomb Protein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Dabomb Protein Biotech (ROCO:6578) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$14.55, compared to a current price of NT$16.50 — trading 13.4% above its estimated fair value. The current Current Ratio is 2.67, which is 15% above median its 10-year median of 2.32 and 54.3% above the Consumer Packaged Goods industry median of 1.73. Dabomb Protein Biotech's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Dabomb Protein Biotech (ROCO:6578), the current Current Ratio is 2.67 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dabomb Protein Biotech (ROCO:6578) Overvalued in 2026?
Based on GuruFocus' analysis, Dabomb Protein Biotech stock appears to be overvalued.
The current stock price of NT$16.50 is trading 13.4% above its estimated GF Value™ of NT$14.55.
GuruFocus considers Dabomb Protein Biotech to be Modestly Overvalued.
Key valuation signals for ROCO:6578:
Current Ratio: 2.67 (15% above median its 10-year median of 2.32)
GF Value™: NT$14.55 vs. price of NT$16.50 (13.4% above fair value)
Industry Position: 54.3% above the Consumer Packaged Goods median (#591 of 1986)
No single metric tells the full story. See the ROCO:6578 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dabomb Protein Biotech Corp is engaged in the manufacture, wholesale, and sale of hydrolyzed soy protein. The products of the company include Plant protein, Antibiotics alternatives, Pet care, Core technology, and CDMO(ODM/OEM). The company operates in a single segment engaged in the manufacture, wholesale and sales of hydrolysed soy protein. Geographically it operates in Malaysia, Taiwan, USA, Vietnam, and Others with majority of the revenue deriving from Vietnam.
59GF Score
Get the complete analysis for ROCO:6578
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6578 has been successfully added to your 
